27 Steps
Maximum: 12.25 CME cr., 12.25 CE ch., 12.25 MOC pts.
0 new discussion posts (2 published)
Sign in to view your progression
Program overview
Learning objectives
Target audience
Credit Designation
Disclosure/Disclaimer

The 2017 Clinical Hepatology Course is a prime opportunity for hepatology professionals to stay updated on the state-of-the-art management of liver disease. Presentations offer clinically relevant insights on many aspects in patient care in liver disease, and a chance to discuss controversies commonly seen in clinical practice with key leaders in the field. This course will offer didactic lectures in 6 topic areas relevant to mid-level hepatology professionals. A breakout session titled Preventative Health Strategies in the Outpatient Management of Cirrhosis will feature a small, interactive discussion with session organizers and networking opportunities with other attendees.

Core Competencies

  • Patient-centered Care
  • Work in Interdisciplinary
  • Quality Improvement
  • Practice Based Learning and Improvement
  • Cognitive Expertise
  • Patient Care
  • Medical Knowledge

 

Program Chairs:

  • K. Rajender Reddy, MD, FAASLD
  • Mark J. Czaja, MD, FAASLD

 

Content Providers:

  • HoChong Gilles, RN, MS, FNP-C
  • Patrick M. Horne, MSN, ARNP, FNPBC
  • April G. Morris, FNP

 

COMPONENTS

Online:

  • 25 online interactive, recorded sessions, 20-25 minutes in length
  • Pre- and post-activity questionnaire
  • Learning quiz for each module

 

  • Media: Internet
  • Original release date: October 16, 2017
  • Expiration date: October 15, 2018
  • Time to complete each module: 30 - 35 minutes

 

System Requirements:

iPad/iPhone: iOS iPad or iPhone devices with iOS 7.0 with the latest LiverLearning® iOS App installed. Click here to download it: LiverLearning® iOS App

Android devices: Not available but coming soon within future upgrades of the LiverLearning® Android App.

Desktop/Laptop Requirements: Medium or Combination of Media Used:

- A recent web browser (cookies and javascript enabled) compatible with HTML5 applications

- Flash Player 9+ is required in order to view the modules and complete the accredited course. If you cannot start a module please click here to download and install the current version of the Flash Player.

- Operating system: MacOS/Windows

Internet Connection: Broadband is recommended but not a must, users in locations with slow internet connection or with a 3G connection may participate in this program. While it is in the best interest of participants to take the exam through a broadband connection or an LTE (4G) cellular connection rather than through a much slower connection, it is not an absolute requirement.

Screen Resolution: iOS Apps: this complete program will adapt itself to fit with iPhone or iPad screens Desktop/Laptop Screens: 800 x 600 or better, 1024 x 768 is preferred

Copyright: All faculty in this activity have given their permission for publication OR ©2017 AASLD

Contact Information: For questions on CME/CE content or the activity web site, contact education@aasld.org.

Upon completion of this activity, learners will be able to:

  • Discuss controversies in disease diagnosis and/or management in patients with a broad range of liver disease.
  • Assess and implement new mechanistic insights and treatment tools with broad application to patients with liver disease.
  • Apply new skills to patient care learned through direct interaction with faculty from case-based discussion.
  • Clinical researchers in the field of liver disease
  • Fellows/Trainees
  • Gastroenterologists
  • Hepatologists
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists
  • Primary care MDs
  • Surgeons
  • Nurses

Satisfactory completion 

Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AASLD designates this enduring activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

American Board of Internal Medicine (ABIM) MOC Statement 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics (ABP) MOC Statement

“Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 12.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

MOC Points Process

Physicians seeking MOC points must complete the CME evaluation in addition to completing the pre-test(s), viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month. Your MOC points will NOT be reported to ABIM and/or ABP until you are completely done with all lectures and the “Final Evaluation & Certificate/Completion Confirmation” step.

Nurse

Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


This course is co-provided by Amedco and the American Association for the Study of Liver Diseases.  Maximum of number of 12.25 hours.


You must complete the pre-test(s), view all of the presentation(s), successfully pass all of the post-test(s) for each module with a score of 70% or better and complete an evaluation to receive a certificate of completion.

AASLD is an accredited CME provider and requires that its speakers comply with the ACCME standards for commercial support of CME. AASLD requires completion of the disclosure form for our records.

Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device.

Speakers provided the following information regarding significant relationships with companies:

Juan G. Abraldes, MD
Speaking and Teaching: Lupin Pharmaceuticals

Christopher L. Bowlus, MD, FAASLD
Grants/Research Support: Gilead Biosciences, Intercept Pharmaceuticals, CymaBay Pharmaceuticals, Takeda Pharmaceuticals, NGM Biosciences, Novartis, GlaxoSmithKline, Merck, BristolMyerSquibb Advisory Committees and/or Review Panels: Intercept Pharmaceuticals, GlaxoSmithKline, BristolMyersSquibb Speaking and Teaching: Gilead Biosciences, Intercept Pharmaceuticals

Kathleen E. Corey, MD, MPH, MMSc
Advisory Committees and/or Review Panels: Gilead Speaking and Teaching: Synageva

Mark J. Czaja, MD, FAASLD
Advisory Committees and/or Review Panels: Verlyx Pharma Inc.

Timothy J. Davern, MD
Nothing to Disclose

Hashem B. El-Serag, MD, MPH
Nothing to Disclose

Michael B. Fallon, MD, FAASLD
Nothing to Disclose

HoChong Gilles, RN, MS, FNP-C
Nothing to Disclose

Patrick M. Horne, MSN, ARNP, FNP-BC
Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

Patrick S. Kamath, MD
Advisory Committees and/or Review Panels: Sequana, Ferring

Saul J. Karpen, MD, PhD, FAASLD
Consulting: Intercept Pharmaceuticals, Retrophin

Jennifer C. Lai, MD
Consulting: Third Rock Ventures, LLC

Frank Lammert, MD, PhD
Nothing to Disclose

Michael R. Lucey, MD, FAASLD
Grants/Research Support: Abbvie, Gilead, Hologic

K. Rajender Reddy, MD, FAASLD
Advisory Committees or Review Panels: Abbvie, BMS, Gilead, Merck Grant/Research Support: AbbVie, BMS, Gilead, Ikaria, Janssen, Merck, Intercept

Michael L. Schilsky, MD, FAASLD
Grants/Research Support: Wilson Therapeutics Advisory Committees or Review Panels: Wilson Therapeutics, GMPO Speaking and Teaching: Gilead

Bernd Schnabl, MD
Advisory Committees or Review Panels: Host Therabiomics Grants/Research Support: NGM Biopharmaceuticals, Ritter Pharmaceuticals

R. Todd Stravitz, MD
Grants/Research Support: TEM, Inc.

Ram M. Subramanian, MD
Nothing to Disclose

Jayant A. Talwalkar, MD, MPH, FAASLD
Advisory Committees or Review Panels: AGA Council Chair of Liver-Biliary Section

Tram T. Tran, MD, FAASLD
Advisory Committees or Review Panels: Gilead, BMS, AbbVie, Merck Grants/Research Support: Gilead, AbbVie, BMS Consulting: Gilead, BMS, AbbVie, Merck

Natalie J. Torok, MD, MSc, FAASLD
Nothing to Disclose

Kymberly Watt, MD
Other (eg. Expert testimony): Intercept - site- PI; Gilead - site PI; Conatus - site co-I; Novartis - previous site PI, co-author study sub analysis all multicenter study related

ONLINE LEARNING COMMITTEE

Calvin Q. Pan, MD, MACP, FAASLD
Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

Lopa Mishra, MD, FAASLD
Nothing to Disclose

Gene Y Im, MD
Nothing to Disclose

Iris W Liou, MD
Nothing to Disclose

Jesse M Civan, MD
Education: Merck

HoChong Gilles, FNP
Nothing to Disclose

Julius Wilder, MD, PhD
Nothing to Disclose

Nicolas M Intagliata, MD
Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

Andrew S. deLemos, MD
Consulting: Novartis

Samar H. Ibrahim, MBCHB
Nothing to Disclose

Acknowledgement of Commercial Support:
No commercial support was received for this enduring activity

Welcome and Introduction
Non-Invasive Diagnosis and Staging of Liver Disease
MOC/CME/CE
Genetic Markers in Liver Disease Diagnosis and Treatment
MOC/CME/CE
FXR: What it is and How it Can Be Targeted for the Treatment of Liver Diseases
MOC/CME/CE
Contribution of the Microbiota in Liver Disease and its Therapy
MOC/CME/CE
Nutritional Issues in Advanced Liver Disease
MOC/CME/CE
What to Do About the Pulmonary Manifestations of Cirrhosis
MOC/CME/CE
Advances in the Management of Ascites and Variceal Hemorrhage
MOC/CME/CE
Care of the Patient with Acute Liver Failure
MOC/CME/CE
Preventative Health Strategies in the Outpatient Management of Cirrhosis
MOC/CME/CE
Current and Evolving Treatments for Alcoholic Hepatitis
MOC/CME/CE
What Can I Treat My NASH Patients With?
MOC/CME/CE
Do We Have A Treatment For Hepatic Fibrosis?
MOC/CME/CE
Emerging Treatments For Cholestatic Liver Diseases
MOC/CME/CE
Controversial Indications for Liver Transplantation: Alcoholic Hepatitis, HCC Outside of Criteria, and Porto-Pulmonary Hypertension
MOC/CME/CE
Principles of ICU Care in Advanced Cirrhosis
MOC/CME/CE
Post-Transplant Care of the Recipient: The Role of the Community Gastroenterologist/Hepatologist
MOC/CME/CE
Coagulopathy in Liver Disease
MOC/CME/CE
Wilson Disease: Diagnosis and Uncommon Presentations
MOC/CME/CE
Acute on Chronic Liver Failure: Is This a Distinct Entity?
MOC/CME/CE
HCC: Who to Screen and How to Treat
MOC/CME/CE
Pediatric Liver Disease: What A General Gastroenterologist/Hepatologist Should Know
MOC/CME/CE
What Do We Do with the HCV Non-Responder
MOC/CME/CE
Treatment of HCV in Decompensated Cirrhosis: Treat Pre or Post-Transplant
MOC/CME/CE
HBV Therapy: Do We Ever Stop Therapy and When?
MOC/CME/CE
Hepatitis E: Is it a Concern in the US?
MOC/CME/CE
Final Evaluation & Certificate/Completion Confirmation